IRON

Disc Medicine Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 1/10
  • Value↑ 6/10
Disc Medicine sales and earnings growth
IRON Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -51.77%
  • FCF Y/Y↓ -92.02%
Disc Medicine gross and profit margin trends
IRON Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 600.07%
Disc Medicine net debt vs free cash flow
IRON Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -57.7

Disc Medicine stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗